Ranbaxy Rules Out "At-Risk" Lipitor Launch: Report
Chief Executive Brian Tempest told Reuters that he would await the outcome of any appeal before introducing a generic version of the cholesterol-lowering medicine in the United States.
“We wouldn't launch at risk. We are a conservative company. We will wait until the appeal at the federal level,” Tempest told the...
To view the full article, register now.